|Benefit-Cost Summary Statistics Per Participant|
|Taxpayers||$1,167||Benefits minus costs||($18,446)|
|Participants||$1,430||Benefit to cost ratio||($0.06)|
|Others||$597||Chance the program will produce|
|Indirect||($4,233)||benefits greater than the costs||0 %|
|Net program cost||($17,406)|
|Benefits minus cost||($18,446)|
|Meta-Analysis of Program Effects|
|Outcomes measured||Treatment age||No. of effect sizes||Treatment N||Adjusted effect sizes(ES) and standard errors(SE) used in the benefit - cost analysis||Unadjusted effect size (random effects model)|
|First time ES is estimated||Second time ES is estimated|
Opioid use disorder
Clinical diagnosis of opioid use disorder or symptoms on a validated scale.
Problem alcohol use
Alcohol use reflecting problem behaviors (e.g., high frequency drinking, binge drinking, or drinking that has a high impact on daily life) for individuals who do not have an alcohol use disorder.
|Detailed Monetary Benefit Estimates Per Participant|
|Affected outcome:||Resulting benefits:1||Benefits accrue to:|
|Problem alcohol use||Property loss associated with problem alcohol use||$0||$0||$0||$0||$0|
|Opioid use disorder||Criminal justice system||$0||$0||$0||$0||$1|
|Labor market earnings associated with opioid drug abuse or dependence||$397||$932||$0||$0||$1,328|
|Health care associated with opioid drug abuse or dependence||$595||$85||$596||$297||$1,573|
|Mortality associated with opioids||$176||$413||$0||$4,173||$4,761|
|Program cost||Adjustment for deadweight cost of program||$0||$0||$0||($8,703)||($8,703)|
|Detailed Annual Cost Estimates Per Participant|
|Annual cost||Year dollars||Summary|
|Program costs||$16,356||2015||Present value of net program costs (in 2018 dollars)||($17,406)|
|Comparison costs||$0||2015||Cost range (+ or -)||10 %|
Benefits Minus Costs
Benefits by Perspective
Taxpayer Benefits by Source of Value
|Benefits Minus Costs Over Time (Cumulative Discounted Dollars)|
|The graph above illustrates the estimated cumulative net benefits per-participant for the first fifty years beyond the initial investment in the program. We present these cash flows in discounted dollars. If the dollars are negative (bars below $0 line), the cumulative benefits do not outweigh the cost of the program up to that point in time. The program breaks even when the dollars reach $0. At this point, the total benefits to participants, taxpayers, and others, are equal to the cost of the program. If the dollars are above $0, the benefits of the program exceed the initial investment.|
Comer, S.D., Sullivan, M.A., Yu, E., Rothenberg, J.L., Kleber, H.D., Kampman, K., . . . O'Brien, C.P. (2006). Injectable, sustained-release naltrexone for the treatment of opioid use disorder: A randomized, placebo-controlled trial. Archives of General Psychiatry, 63(2), 210-218.
Krupitsky, E., Nunes, E.V., Ling, W., Illeperuma, A., Gastfriend, D.R., & Silverman, B.L. (2011). Injectable extended-release naltrexone for opioid use disorder: A double-blind, placebo-controlled, multicentre randomised trial. Lancet, 377(9776), 1506-1513.
Lee, J.D., McDonald, R., Grossman, E., McNeely, J., Laska, E., Rotrosen, J., & Gourevitch, M.N. (2015). Opioid treatment at release from jail using extended-release naltrexone: A pilot proof-of-concept randomized effectiveness trial. Addiction, 110(6), 1008-1014.
Lee, J.D., Friedmann, P.D., Kinlock, T.W., Nunes, E.V., Boney, T.Y., Hoskinson, R.A., . . . O’Brien, C.P. (2016). Extended-release naltrexone to prevent opioid relapse in criminal justice offenders. New England Journal of Medicine, 374(13), 1232-1242.